Currently, there are not vaccines or specific drugs for treating the chikungunya virus, which is spread by mosquitoes.
Ths vaccine was first tested successfully in 2010 on non-human primates. It was later tested on 23 volunteers over a 20-week period. Over this period, it was found that the body was able to produce chikungunya neutralising antibodies in all volunteers from the scond week onwards.
Chikungunya causes severe joint pains accompanied by headache and fever.
While traditional vaccines are made from either killed viruses or from weakened live viruses, the experimental vaccine used in the trial was a virus-like particle (VLP) vaccine.